Quick Answer
KYNTRA BIO, INC. reported Diluted EPS of $45.37 per share for fiscal year 2025.
KYNTRA BIO, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $45.37 | +481.6% |
| 2024 | -$11.89 | -307.2% |
| 2023 | -$2.92 | +7.0% |
| 2022 | -$3.14 | +0.0% |
| 2021 | -$3.14 | -48.8% |
| 2020 | -$2.11 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $49.61 | +1267.3% | +2738.8% |
| June 30, 2025 | -$1.88 | +51.7% | -3860.0% |
| March 31, 2025 | $0.05 | +115.2% | +101.2% |
| September 30, 2024 | -$4.25 | -553.8% | -9.3% |
| June 30, 2024 | -$3.89 | -332.2% | -1078.8% |
| March 31, 2024 | -$0.33 | +59.3% | +49.2% |
| September 30, 2023 | -$0.65 | +33.7% | +27.8% |
| June 30, 2023 | -$0.90 | -15.4% | -11.1% |
- KYNTRA BIO, INC. showed an increase of +481.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, KYNTRA BIO, INC.’s diluted eps has grown by 2250.2% (from $2.11 per share (loss) to $45.37 per share).
- The most recent figure is from KYNTRA BIO, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: